Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network

Siegel, 2021, Cancer statistics, 2021, CA Cancer J. Clin., 71, 7, 10.3322/caac.21654 Howlader, 2020 Lindeman, 2018, Arch. Pathol. Lab. Med., 142, 321, 10.5858/arpa.2017-0388-CP Gregg, 2019, Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey, Transl. Lung Cancer Res., 8, 286, 10.21037/tlcr.2019.04.14 Aisner, 2021, Non-small cell lung cancer: recommendations for biomarker testing and treatment, J. Natl. Compr. Cancer Netw., 19, 610, 10.6004/jnccn.2021.5020 Kim, 2019, Updates regarding biomarker testing for non-small cell lung cancer: considerations from the national lung cancer roundtable, J. Thorac. Oncol., 14, 338, 10.1016/j.jtho.2019.01.002 Mok, 2017, Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer, N. Engl. J. Med., 376, 629, 10.1056/NEJMoa1612674 Rosell, 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol., 13, 239, 10.1016/S1470-2045(11)70393-X Peters, 2017, Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer, N. Engl. J. Med., 377, 829, 10.1056/NEJMoa1704795 Enewold, 2016, Real-world patterns of EGFR testing and treatment with erlotinib for non-small cell lung cancer in the United States, PLoS One, 11, 10.1371/journal.pone.0156728 Kwak, 2010, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer, N. Engl. J. Med., 363, 1693, 10.1056/NEJMoa1006448 Schwegler, 2018, Population-level effect of molecular testing and targeted therapy in patients with advanced pulmonary adenocarcinoma: a prospective cohort study, Virchows Arch., 472, 581, 10.1007/s00428-017-2268-y Hirsch, 2018, Molecular and immune biomarker testing in squamous-cell lung cancer: effect of current and future therapies and technologies, Clin. Lung Cancer, 19, 331, 10.1016/j.cllc.2018.03.014 Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N. Engl. J. Med., 373, 1627, 10.1056/NEJMoa1507643 Majeed, 2021, Targeted therapy in advanced non-small cell lung cancer: current advances and future trends, J. Hematol. Oncol., 14, 108, 10.1186/s13045-021-01121-2 Robert, 2021, Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices, J. Clin. Oncol., 39, 9004, 10.1200/JCO.2021.39.15_suppl.9004 Gierman, 2019, genomic testing and treatment landscape in patients with advanced non-small cell lung cancer (aNSCLC) using real-world data from community oncology practices, J. Clin. Oncol., 37, 1585, 10.1200/JCO.2019.37.15_suppl.1585 Khan, 2018, ALK inhibitors in the treatment of ALK positive NSCLC, Front. Oncol., 8, 557, 10.3389/fonc.2018.00557 Joshi, 2019, ROS1 mutation non-small cell lung cancer-access to optimal treatment and outcomes, Ecancermedicalscience, 13, 900, 10.3332/ecancer.2019.900 Alvarez, 2019, Agents to treat BRAF-mutant lung cancer, Drugs Context, 8 Wu, 2020, Osimertinib in resected EGFR-mutated non-small-cell lung cancer, N. Engl. J. Med., 383, 1711, 10.1056/NEJMoa2027071 Felip, 2021, Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial, Lancet, 398, 1344, 10.1016/S0140-6736(21)02098-5 Yu, 2018, Budget impact of next-generation sequencing for molecular assessment of advanced non-small cell lung cancer, Value Health, 21, 1278, 10.1016/j.jval.2018.04.1372 Tan, 2018, Application of next-generation sequencing to improve cancer management: a review of the clinical effectiveness and cost-effectiveness, Clin. Genet., 93, 533, 10.1111/cge.13199 Pennell, 2019, Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non–small-cell lung cancer using a decision analytic model, JCO Precis. Oncol., 2019 Audibert C.M., Shea M.B., Glass D.J., et al. Friends of cancer research white paper: trends in the molecular diagnosis of lung cancer; results from an online market research survey. July 20, 2016. https://friendsofcancerresearch.org/publications/trends-molecular-diagnosis-lung-cancer-results-online-market-research-survey. Accessed: October 1,2021. Peters, 2017, Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer, N. Engl. J. Med., 377, 829, 10.1056/NEJMoa1704795 Nadler, 2018, Treatment patterns and clinical outcomes among metastatic non-small-cell lung cancer patients treated in the community practice setting, Clin. Lung Cancer, 19, 360, 10.1016/j.cllc.2018.02.002 Ganti, 2018, P2.03b-048 access to biomarker testing in patients with advanced non-small cell lung cancer, J. Thorac. Oncol., 12, S964, 10.1016/j.jtho.2016.11.1329 Lim, 2015, Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer, Ann. Oncol., 26, 1415, 10.1093/annonc/mdv208